ReviewNaunyn-Schmiedeberg's archives of pharmacology2006
Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Enhancement of Sphingomyelinase-Induced Endothelial Nitric Oxide Synthase-Mediated Vasorelaxation in a Murine Model of Type 2 Diabetes.International journal of molecular sciences · 2023Article
- Sphinganine is associated with 24-h MAP in the non-sleepy with OSA.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- JNK-dependent phosphorylation and nuclear translocation of EGR-1 promotes cardiomyocyte apoptosis.Apoptosis : an international journal on programmed cell death · 2022Article
- Sphingosine 1 phosphate promotes hypertension specific memory T cell trafficking in response to repeated hypertensive challenges.Frontiers in physiology · 2022Article
- The imbalance in the aortic ceramide/sphingosine-1-phosphate rheostat in ovariectomized rats and the preventive effect of estrogen.Lipids in health and disease · 2020Article
- Sphingolipid Mediators of Myocardial Pathology.Journal of lipid and atherosclerosis · 2020Review
- Sphingosine-1-Phosphate Enhances αInternational journal of molecular sciences · 2019Article
- Sphingosine-1-phosphate signaling in blood pressure regulation.American journal of physiology. Renal physiology · 2019Review
- Vascular protection by high-density lipoprotein-associated sphingosine-1-phosphate.Journal of geriatric cardiology : JGC · 2017Review
- A Dormant Microbial Component in the Development of Preeclampsia.Frontiers in medicine · 2016Review
- Pericyte chemomechanics and the angiogenic switch: insights into the pathogenesis of proliferative diabetic retinopathy?Investigative ophthalmology & visual science · 2015Article
- Network-based analysis of the sphingolipid metabolism in hypertension.Frontiers in genetics · 2015Article
- Effect of sphingosine kinase 1 inhibition on blood pressure.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Effects of sphingosine-1-phosphate on pacemaker activity of interstitial cells of Cajal from mouse small intestine.Molecules and cells · 2013Article
- The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis.Lymphatic research and biology · 2012Review
- Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.British journal of pharmacology · 2011Review
- Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension.BMC genetics · 2011Article
- The impact of bioactive lipids on cardiovascular development.Stem cells international · 2011Article
- Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery.British journal of pharmacology · 2010Article
- "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.Pharmacological reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two related lysosphingolipids, sphingosine 1-phosphate (S1P) and sphingosylphosphorylcholine (SPC) mediate diverse cellular responses through signals transduced by either activation of G-protein coupled receptors or possibly by acting intracellularly. Vascular responses to S1P and SPC measured both in vivo and in dissected vessels show predominantly vasoconstriction with some evidence for vasodilation. Although stimulation with S1P or SPC generally leads to similar vascular responses, the signalling pathways stimulated to produce these responses are often distinct. Nevertheless, mobilization of Ca2+ from intracellular stores and influx of extracellular Ca2+, which both increase [Ca2+]i, occur in response to S1P and SPC. Both mobilization of Ca2+ from intracellular stores and influx of extracellular Ca2+ occur in response to S1P and SPC. As well, both S1P and SPC induce Ca2+-sensitization in vascular smooth muscle which is mediated through Rho kinase activation. In the endothelium, S1P and SPC stimulate the production of the vasodilator, nitric oxide through activation of endothelial nitric oxide synthase. This activation occurs through phosphorylation by Akt and through binding of Ca2+-calmodulin upon increased [Ca2+]i. These lysosphingolipids also activate cyclooxygenase-2 which produces prostaglandins with both vasoconstrictor and vasodilator properties. A balance between the signals inducing vasodilation versus the signals inducing vasoconstriction will determine the vascular outcome. Thus, perturbations in S1P and SPC concentrations, relative expression of receptors or downstream signalling pathways may provide a mechanism for pathophysiological conditions such as hypertension. Given this background, recent studies examining a potential role for S1P and SPC in hypertension and vascular dysfunction in aging are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.